Safety of two cancer drugs after liver transplant
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) for people whose liver cancer has returned after a liver transplant and cannot be treated with surgery or other local procedures. The goal is to see if this treatment is safe for liver transplant recipients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 90 years old.
- You had a liver transplant more than 6 months ago.
- Your liver cancer has come back after transplant and cannot be treated with surgery or local treatments.
- You have at least one tumor that hasn't been treated yet and can be measured.
- Your liver function is good (Child-Pugh class A).
- Your blood counts and kidney function are within certain safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of two immunotherapy drugs before a liver transplant can help people with advanced liver cancer (beyond standard size limits) receive a transplant successfully. The treatment aims to shrink the tumor and improve outcomes.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This trial tests giving a low dose of two drugs (bevacizumab and atezolizumab) alongside standard local treatments (TACE and HAIC) for liver cancer that cannot be removed with surgery. The goal is to see if this combination helps control the tumor better or improves outcomes.
This trial tests whether adding two drugs (atezolizumab and bevacizumab) before and after surgery can lower the chance of liver cancer coming back in people with high-risk HCC. You must be eligible for surgical removal of your tumor.
Hear when a new Liver Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.